Lemonade posted its best quarter in company history on February 19. Revenue up 53%. Gross profit up 73%. Free cash flow positive for the third consecutive quarter. The EPS loss was cut nearly in half versus what analysts expected. By every operational metric, Q4 2025 was Lemonade’s finest hour.
The stock opened 13.9% higher in premarket. Ninety minutes after the open, it was down 6.8%. By end of day it had settled to a 5.5% loss. Friday brought another 4.9% decline to $57.15. From the pre-earnings close of $65.60, the stock is now down roughly 13% — despite the best set of numbers the company has ever produced.
That gap between business performance and stock price is the LMND story right now. Here’s the full breakdown.
Q4 2025: The Numbers
Results reported February 19, 2026:
- In-force premium (IFP): $1.24 billion, up 31% year-over-year. This marks nine consecutive quarters of accelerating growth — not just growing, but growing faster each period.
- Revenue: $228.1 million, up 53% YoY. Beat analyst consensus of $216–220 million.
- EPS: -$0.29, beating the -$0.39–$0.41 consensus by $0.12.
- Gross profit: $111 million, up 73% YoY. Gross margin at 48%.
- Adjusted EBITDA: -$5 million, a $19 million improvement versus Q4 2024. Near breakeven.
- Adjusted free cash flow: +$37 million (up from +$27 million in Q4 2024). Positive for the third straight quarter; positive in six of the last seven quarters.
- Net loss: $22 million (-$0.29/share) vs. $30 million (-$0.42/share) in Q4 2024.
- Customer growth: 550,000 net new customers added in full-year 2025 — a 35% increase over 2024, with the total customer base up 23%.
- Cross-sell penetration: Over 5% of customers hold two or more Lemonade products, contributing nearly 20% of total in-force premium.
- Annual Dollar Retention (ADR): 85%, stable versus Q3.
- Headcount: 1,282 employees — up just 4% YoY. The unit economics are improving; the headcount isn’t bloating.
There isn’t a weak metric on that list. Gross profit has compounded at a triple-digit annual rate over the past three years. The model is working. CEO Daniel Schreiber put it plainly: “By any measure, this was our strongest quarter ever.”
2026 Guidance: Above Estimates
For full-year 2026, management guided:
- Revenue: $1.187B–$1.192B (~60% growth vs. estimated FY2025 revenue of ~$742 million). Beat analyst estimate of $1.158 billion.
- IFP: $1.625B–$1.630B (32% growth)
- Adjusted EBITDA: Positive in Q4 2026; positive for the full year of 2027
- Growth spend (sales & marketing): $225 million
That revenue guide beat the Street. The EBITDA path is concrete — not “sometime in the future” but Q4 2026, with a full-year 2027 target. Lemonade has been building to this. Now there’s a specific quarter attached to the promise.
The Tesla FSD Play: The Angle Nobody Else Is Pricing
The most interesting thing about Lemonade in 2026 isn’t its financials. It’s an insurance product that launched in January and could reshape how auto insurance is priced for the next decade.
Lemonade launched autonomous car insurance for Tesla vehicles with Full Self-Driving (FSD) enabled. The pricing model works in three modes: parked, human-driven, and AI-driven. When Tesla’s FSD system controls the vehicle, those miles are priced at roughly 50% of what a human-driven mile costs. When a human is driving, standard pricing applies.
Traditional auto insurers use proxies — credit scores, marital status, occupation — because they can’t observe the actual driving. These are blunt instruments that correlate with risk but don’t measure it directly. Telematics got closer, but it still measures human behavior. Lemonade’s system measures the AI itself. President Shai Wininger said it plainly on the earnings call: “As autonomous driving becomes safer and more widely adopted, prices should fall transparently, dynamically.”
The product is already available to 60% of Lemonade’s existing customers, covering states that represent roughly 50% of the U.S. car insurance market. It’s too early to show in revenue. But if autonomous driving scales — and it will — Lemonade’s AI pricing data advantage over Progressive, GEICO, and State Farm compounds with every mile driven. The incumbents can build a competing product. They can’t buy back the years of training data.
Car insurance IFP is already growing in the 50% range. Pet insurance: same. Europe: triple-digit IFP growth. These aren’t rounding errors — they’re becoming real, diversified business lines that reduce Lemonade’s dependence on any single product.
Why the Stock Fell on the Best Quarter in Company History
Going into earnings, LMND was trading at 8.9 times trailing sales. For context: the average property and casualty insurer trades at 1.4x sales. The sector’s highest-priced conventional insurer, Kinsale Capital Group, sits at 4.7x. Lemonade was priced at 6x the industry average before the report dropped.
When you’re priced that high, “best quarter ever” isn’t enough. The market needs something transcendent — and transcendent is a moving target. The results were genuinely excellent, but they were at least partially priced in after a huge run from the $24.31 52-week low. The EBITDA profitability is still 11 months away at the earliest. Wall Street doesn’t pay a premium today for profits arriving in late 2026 from a company still posting GAAP losses of -$3.03 per share (analyst consensus) for the year ahead.
Short interest added the volatility. Going into earnings, 18.8% of LMND’s float was short — roughly five days of trading volume worth of covered buying pressure if a squeeze materialized. The premarket surge to $74+ looked like it was starting. By 10 AM, long-term holders took profits, shorts held, and the stock reversed 20 points in 90 minutes. By Friday it had given back everything and then some.
LMND now sits near $57 — below its 50-day moving average of $77.90 and below its 200-day MA of $66.08 — despite the best fundamentals it’s ever shown. That’s the tension. Beta is 2.03. This stock moves violently in both directions.
The Bear Case
Three things that argue for waiting:
GAAP losses are real and persistent. The Q4 net loss was $22 million. Full-year 2026 analyst EPS consensus is -$3.03. The adjusted FCF positive is genuine, but GAAP profitability is years out. Paying $4.3 billion for a company burning money on a GAAP basis requires genuine conviction that the AI moat is durable enough to justify the wait.
Every executive is selling. In the past six months, Lemonade insiders made 0 purchases and 25 sales. CEO Daniel Schreiber sold 126,625 shares for roughly $12.9 million. COO Adina Eckstein sold 132,620 shares for ~$10.2 million. Two executives, $23 million in combined sales, all in the past six months, all on the way down. Management may have long-term conviction in the business — but they’re not buying the stock at these prices, and that says something.
ADR is stuck at 85%. Annual dollar retention has sat at 85% for multiple consecutive quarters now. That’s not a disaster, but for a company commanding a 6x premium to the insurance sector on the premise of AI-driven customer relationships, retention should be improving, not flat. Progressive and Kinsale both post higher retention. Until LMND moves ADR above 88–90%, the AI advantage in underwriting isn’t translating to customer stickiness the way bulls want to believe.
What the Analysts Think
Coverage is divided in a way that’s unusual even for a controversial name:
- Ratings breakdown: 4 Buy, 2 Hold, 3 Sell
- Consensus target: $71.71 (25% above current ~$57)
- Piper Sandler: $65.00 (set post-earnings, February 19)
- Morgan Stanley: $85.00 Equal Weight (December 2025)
- Keefe, Bruyette & Woods: $40.00 Underperform
The spread from $40 to $85 tells you how genuinely uncertain the outlook is. KBW’s bear case says the AI premium isn’t justified and you should own an insurer that actually makes money. Morgan Stanley’s bull case says the autonomous insurance moat is real and the market undervalues it. Both arguments are coherent. That’s exactly why this is interesting.
The Verdict
The business is turning a corner. Nine consecutive quarters of accelerating in-force premium growth. Consistent positive free cash flow. Near-EBITDA breakeven. The autonomous car insurance product has real differentiating potential that legacy insurers can’t easily replicate. These are legitimate signals, not narrative dressing.
The problem is valuation. At $57, you’re paying roughly 7–8x forward sales for a company still generating -$3 EPS for the year ahead. Executing on 60% revenue growth in 2026 while simultaneously hitting Q4 EBITDA profitability isn’t impossible — but it’s a high bar. Any stumble on either front and the stock revisits $40.
Compelling entry: $48–50. That’s still elevated for a P/C insurer, but it gives you more margin if execution slips. If LMND hits the low $40s on a guidance miss, that’s where the risk/reward flips decisively — at 5x forward sales with the EBITDA path intact, you’re getting paid to wait.
The single metric to watch at Q1 2026 earnings: ADR. If it moves above 87%, the AI advantage is showing up in customer retention and the valuation re-rating has legs. If it stays at 85% or drops, the KBW bear thesis gets stronger. That one number will tell you more than anything management says on the call.
For related analysis of growth-stage tech companies navigating the same profitability transition, see our coverage of Radware (RDWR), Amplitude (AMPL), and Fastly (FSLY).
This is not financial advice. I hold no position in LMND.